Global Policy Gaps Slow Biosimilar Adoption and Access

Why It Matters

Regulatory fragmentation slows biosimilar entry, keeping biologic drug prices high and limiting affordable treatment options for patients worldwide.

Key Takeaways

• Only 5% of prescriptions are biologics yet they exceed 50% spending
• Regulatory pathways for biosimilars differ across 19 surveyed countries
• Some nations allow pharmacy substitution; others require physician approval
• Reliance on foreign data reduces trials, but many regulators demand local studies
• Harmonizing approval could accelerate market entry and cut patient costs

Pulse Analysis

Biosimilars promise to replicate the cost‑efficiency of traditional generics, yet they remain a fraction of the market despite biologics consuming over 50% of pharmaceutical spend. The complexity of producing protein‑based medicines means that manufacturers must navigate extensive clinical and analytical testing, which inflates development costs. As a result, patients often face steep price tags for breakthrough therapies such as Ozempic or oncology biologics, creating a pressing need for affordable alternatives that can be brought to market faster.

The UCSF analysis highlights a patchwork of regulatory frameworks spanning the United States, Europe, Africa, and Asia‑Pacific. Some jurisdictions accept laboratory similarity data and permit pharmacy‑level substitution, while others mandate extensive patient trials and physician‑initiated prescriptions. This lack of harmonization forces companies to duplicate studies, inflate timelines, and increase pricing to recoup investment. Moreover, the requirement for local data in many markets discourages smaller biotech firms from entering the biosimilar space, consolidating market power among a few large players.

Policy experts argue that a coordinated global approach—such as mutual recognition of data, standardized definitions, and streamlined substitution rules—could unlock the full potential of biosimilars. By reducing redundant testing and accelerating approval, patients would gain earlier access to lower‑cost treatments, and health systems could alleviate budget pressures. For pharmaceutical companies, regulatory convergence offers a clearer pathway to scale production and achieve economies of scale, ultimately fostering competition that drives down prices across the biologics segment.